What is the average price target for CONCENTRIX CORP (CNXC) stock?
11 analysts have analysed CNXC and the average price target is 47.12 USD. This implies a price increase of 55.22% is expected in the next year compared to the current price of 30.36.
NASDAQ:CNXC • US20602D1019
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CONCENTRIX CORP (CNXC).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-25 | Barrington Research | Maintains | Outperform -> Outperform |
| 2026-03-25 | Baird | Maintains | Outperform -> Outperform |
| 2026-03-25 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-03-17 | Barrington Research | Maintains | Outperform -> Outperform |
| 2026-01-12 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-11-20 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-09-29 | Baird | Maintains | Outperform -> Outperform |
| 2025-09-26 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-09-26 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-09-24 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-09-23 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-09-18 | Baird | Maintains | Outperform -> Outperform |
| 2025-06-30 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-06-27 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-06-27 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-06-26 | Baird | Maintains | Outperform -> Outperform |
| 2025-06-24 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-06-09 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-03-27 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-03-27 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-03-24 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-01-16 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-10-03 | Baird | Initiate | Outperform |
| 2024-09-26 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-09-26 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.115B 12.49% | 9.619B 35.20% | 9.826B 2.15% | 10.346B 5.29% | 10.604B 2.49% | 11.022B 3.94% | |
| EBITDA YoY % growth | 1.121B 13.98% | 1.459B 30.16% | 1.371B -6.00% | 1.525B 11.20% | 1.599B 4.85% | N/A | |
| EBIT YoY % growth | 732.663M 8.71% | 753.158M 2.80% | 711.011M -5.60% | 1.293B 81.85% | 1.378B 6.57% | N/A | |
| Operating Margin | 10.30% | 7.83% | 7.24% | 12.50% | 13.00% | N/A | |
| EPS YoY % growth | 11.32 -3.58% | 11.39 0.62% | 11.22 -1.49% | 11.94 6.45% | 13.09 9.63% | 15.63 19.35% |
All data in USD
| Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 2.69 -0.36% | 3.15 13.19% | 3.49 18.25% | 3.09 18.54% | 3.27 21.52% | 3.50 11.18% | 3.87 10.96% | 3.52 13.74% | 3.35 2.34% | 3.63 3.79% | 3.88 0.13% |
| Revenue Q2Q % growth | 2.523B 4.37% | 2.583B 4.02% | 2.655B 4.00% | 2.596B 3.82% | 2.602B 3.13% | 2.662B 3.06% | 2.735B 3.01% | 2.687B 3.51% | 2.679B 2.96% | 2.685B 0.86% | 2.755B 0.73% |
| EBITDA Q2Q % growth | 358.02M -27.11% | 393.61M -40.38% | 419.26M -50.89% | 382.92M 6.67% | 396.17M 10.66% | 413.36M 5.02% | 441.76M 5.37% | 450.56M 17.66% | 436.54M 10.19% | 463.13M 12.04% | 485.62M 9.93% |
| EBIT Q2Q % growth | 301.74M 82.70% | 333.28M 101.25% | 357.13M 84.69% | 326.19M 8.13% | 335.73M 11.26% | 351.49M 5.46% | 378.27M 5.92% | N/A | N/A | N/A | N/A |
All data in USD
11 analysts have analysed CNXC and the average price target is 47.12 USD. This implies a price increase of 55.22% is expected in the next year compared to the current price of 30.36.
CONCENTRIX CORP (CNXC) will report earnings on 2026-06-24, after the market close.
The consensus EPS estimate for the next earnings of CONCENTRIX CORP (CNXC) is 2.69 USD and the consensus revenue estimate is 2.52B USD.
The number of analysts covering CONCENTRIX CORP (CNXC) is 11.